Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 159 participants.
Also called NCT07423975
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 159 participants
- Sponsor
- Registry
-
NCT07423975
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07423975. Randomized; single masking; primary purpose treatment. Start 2026-04-08 (actual); primary completion 2026-10-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke
- Acronym
- ARTS-SAFE
- Condition
- Stroke Acute
- Condition
- Endovascular Treatment
- Intervention (Drug)
- High-dose Anakinra
- Intervention (Drug)
- Low-dose Anakinra
- Intervention (Other)
- Standard medical treatment
- Lead sponsor
- Beijing Tiantan Hospital
Record details
- Record id
cardio:ct-nct07423975- Content hash
915d915aec460c2b8bae1e2fed2209651bc3cf5bd588335459d346b39919bf63